Table 5.
Association between isoflavone intake and MPS among breast cancer patients at 6 and 36 months postdiagnosis stratified by BMI, the SBCSS
| Quartiles of isoflavone intake (mg/day) | No. | Multivariate OR (95% CI)a |
|||
|---|---|---|---|---|---|
| Any symptom | Hot flashes | Night sweats | Vaginal dryness | ||
| Intake at 6 months postdiagnosis (n = 4,842) | |||||
| BMI < 27.5 | 4,115 | 2,349 | 1,869 | 1,478 | 393 |
| ≤20.0 | 1,043 | 1.00 | 1.00 | 1.00 | 1.00 |
| 20.01–36.46 | 1,045 | 1.02 (0.85–1.22) | 1.07 (0.89–1.28) | 0.98 (0.82–1.18) | 1.32 (0.98–1.78) |
| 36.47–62.63 | 1,027 | 1.04 (0.87–1.23) | 1.08 (0.88–1.27) | 1.10 (0.91–1.31) | 1.13 (0.83–1.54) |
| > 62.63 | 1,000 | 1.14 (0.94–1.37) | 1.12 (0.93–1.35) | 1.13 (0.94–1.37) | 1.14 (0.84–1.55) |
| P trend | 0.21 | 0.27 | 0.12 | 0.6 | |
| BMI ≥27.5 | 727 | 361 | 268 | 240 | 36 |
| ≤20.0 | 170 | 1.00 | 1.00 | 1.00 | 1.00 |
| 20.01–36.46 | 162 | 1.08 (0.68–1.73) | 1.04 (0.63–1.71) | 0.88 (0.54–1.42) | 0.87 (0.27–2.78) |
| 36.47–62.63 | 185 | 1.26 (0.79–1.99) | 1.00 (0.62–1.63) | 0.93 (0.58–1.48) | 1.11 (0.39–3.24) |
| > 62.63 | 210 | 0.92 (0.59–1.44) | 0.76 (0.47–1.22) | 0.75 (0.47–1.19) | 1.48 (0.54–4.00) |
| P trend | 0.99 | 0.45 | 0.28 | 0.44 | |
| P for interaction | 0.35 | 0.55 | 0.51 | 0.68 | |
| Weighted intake over the first 36 months postdiagnosis (n = 3,472) | |||||
| BMI < 27.5 | 2,934 | 1,867 | 1,638 | 800 | 418 |
| ≤27.28 | 744 | 1.00 | 1.00 | 1.00 | 1.00 |
| 27.28–42.22 | 712 | 1.17 (0.94–1.46) | 1.13 (0.91–1.41) | 1.05 (0.83–1.33) | 1.07 (0.79–1.44) |
| 42.23–62.86 | 768 | 1.10 (0.88–1.37) | 1.10 (0.89–1.37) | 1.03 (0.81–1.30) | 1.09 (0.81–1.46) |
| > 62.86 | 710 | 1.18 (0.94–1.48) | 1.21 (0.97–1.51) | 1.07 (0.84–1.36) | 0.97 (0.71–1.32) |
| P trend | 0.20 | 0.11 | 0.62 | 0.85 | |
| BMI ≥27.5 | 538 | 320 | 266 | 166 | 53 |
| ≤27.28 | 124 | 1.00 | 1.00 | 1.00 | 1.00 |
| 27.28–42.22 | 113 | 1.09 (0.61–1.93) | 1.14 (0.63–2.07) | 1.51 (0.83–2.72) | 0.95 (0.40–2.27) |
| 42.23–62.86 | 144 | 1.20 (0.69–2.08) | 1.28 (0.72–2.26) | 1.20 (0.67–2.14) | 0.77 (0.32–1.84) |
| > 62.86 | 157 | 1.26 (0.74–2.16) | 1.28 (0.74–2.22) | 1.46 (0.84–2.54) | 0.71 (0.30–1.67) |
| P trend | 0.25 | 0.66 | 0.16 | 0.40 | |
| P for interaction | 0.97 | 0.99 | 0.49 | 0.92 | |
a
Adjusted for age at diagnosis, education level (categories), parity (0, 1, 2, and ≥3), vitamin supplement use (yes/no), total meat intake (continuous), Charlson co-morbidity index (0/≥1), regular physical activity (yes/no), menopausal status, perceived quality of life (poor, average, and good), TNM stage, chemotherapy, tamoxifen use, and immunotherapy
Note: BMI was categorized by using the WHO’s cut-offs for Asians (<27.5 vs. ≥27.5 kg/m2, non-obese vs. obese)